Klh-Pulsed Autologous Dendritic Cell Vaccine
Embryonal Rhabdomyosarcoma
National Cancer Institute (NCI)vaccinePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Embryonal Rhabdomyosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vincristine Sulfate Children's Oncology Group | Phase 3 | B |
Dactinomycin Children's Oncology Group | Phase 3 | B |
Vinorelbine Ditartrate Children's Oncology Group | Phase 3 | B |
Cyclophosphamide Children's Oncology Group | Phase 3 | B |
Ixabepilone National Cancer Institute (NCI) | Phase 2 | B |
Allogeneic Tumour Lysate National Cancer Institute (NCI) | Phase 1/2 | CCC |
Interleukin 7 National Cancer Institute (NCI) | Phase 1/2 | CCC |
Same molecule, other indications
Klh-Pulsed Autologous Dendritic Cell Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →